Dr. Lal PathLabs Limited announced the launch of SOVAAKA, its new-age Diagnostic Experience Centre in Gurugram on January 6, 2026. The initiative represents a significant advancement in preventive healthcare, combining precision diagnostics with cutting-edge technology to deliver personalized wellness solutions.

Advanced Wellness Philosophy

Built on the philosophy of "Science Behind Wellness," SOVAAKA introduces a new standard in preventive and lifestyle healthcare. The centre brings together precision diagnostics, cutting-edge technology, and medical expertise to help individuals take proactive control of their health. This advanced wellness initiative goes beyond routine health checks to offer a deeply personalized diagnostics-led wellness experience.

Personalized Programs and Services

SOVAAKA offers doctor-designed programs customized to individual needs:

The centre integrates advanced diagnostics including high-sensitivity blood panels, genetic testing, AI-supported imaging, and seamlessly integrated digital health records. With end-to-end clinical report evaluation and tailored nutrition guidance, SOVAAKA delivers comprehensive understanding of health and wellness trajectory.

Technology and Equipment

The facility is equipped with state-of-the-art medical technology to ensure comprehensive health assessment:

The centre ensures fast turnaround times, comprehensive insights, and deeply personalized evaluation experiences for all patients.

Leadership Perspectives

(Hony) Brig. Dr. Arvind Lal, Executive Chairman of Dr. Lal PathLabs, emphasized the transformative nature of the initiative: "SOVAAKA marks a pivotal moment in the evolution of diagnostics — from disease detection to disease prediction. In a world where Non-Communicable Diseases (NCDs) or Lifestyle Diseases are affecting millions silently, science-led wellness and early screening play a transformative role."

Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, highlighted the comprehensive approach: "With SOVAAKA, we are reimagining how preventive healthcare is delivered. By bringing diagnostics, advanced imaging, and lifestyle-based programmes under one roof, we are creating a destination for individuals committed to investing in their long-term health."

Market Context and Strategic Positioning

The launch comes at a time when India is witnessing rapid growth in the preventive health and wellness segment. This growth is driven by increasing incidence of Non-Communicable Diseases, rising awareness, evolving lifestyles, and greater emphasis on early detection. With SOVAAKA, Dr. Lal PathLabs strengthens preventive care by offering comprehensive, evidence-backed solutions that empower individuals to understand their health better and act early.

SOVAAKA represents the premium wellness vertical from Dr. Lal PathLabs, merging diagnostic excellence, medical expertise, and AI technology to offer personalized, preventive, and predictive health experiences. The centre positions the company at the forefront of the evolving healthcare landscape, focusing on proactive health management rather than reactive treatment approaches.

Dr. Lal PathLabs has successfully completed its bonus share allotment, with the Board of Directors approving the issuance through a circular resolution on December 22, 2025. The company allotted 8,37,75,510 fully paid-up bonus equity shares in the ratio of 1:1 to eligible shareholders.

Bonus Share Allotment Details

The bonus shares were allotted to shareholders whose names appeared in the Register of Members or List of Beneficial Owners as of the record date of December 19, 2025. Each eligible shareholder received one new fully paid-up equity share for every existing share held.

Enhanced Capital Structure

Following the bonus share allotment, the company's paid-up equity share capital has doubled from ₹83.78 crores to ₹167.55 crores. The total number of outstanding shares increased from 8.38 crores to 16.76 crores.

Previous Corporate Actions

Prior to this allotment, the company had announced a second interim dividend of ₹7.00 per equity share for the financial year 2025-26, with a record date of November 7, 2025. The company had also paid an earlier interim dividend of ₹6.00 per share in August 2025.

The bonus shares allotted rank pari-passu in all respects with the existing fully paid-up equity shares of the company. The allotment was funded from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.